Abstracts tagged "methotrexate (MTX)"

Abstract Number: 355 • 2012 ACR/ARHP Annual Meeting
Metaanalysis of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Transformylase (ATIC) 347C>G Polymorphism Affecting Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis Patients
Fardina Malik¹ and Prabha Ranganathan², ¹Internal Medicine, Alton Memorial Hospital, Alton, IL, ²Div of Rheumatology, Washington Univ School of Med, St. Louis, MO
Background/Purpose: Methotrexate (MTX) exerts its effect in part by inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), a key enzyme in the purine biosynthetic pathway. Published data suggests…
Abstract Number: 1722 • 2012 ACR/ARHP Annual Meeting
Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Linda C. Li¹, Anne F. Townsend², Paul M. Adam³, Catherine L. Backman⁴, Sydney Brooks⁵, Gwen A. Ellert⁶, Allyson Jones⁷, Otto Kamensek⁸, Cheryl Koehn⁹, Diane Lacaille⁸, Jenny Leese², Colleen Maloney⁸, Elaine Yacyshyn¹⁰, Charlene Yousefi⁸ and Dawn Stacey¹¹, ¹Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁵The Arthritis Society, Ontario Division, Toronto, ON, Canada, ⁶Health Education, Trelle Enterprises Inc, Vancouver, BC, Canada, ⁷Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Arthritis Consumer Experts, Vancouver, BC, Canada, ¹⁰562 Heritage Med Rsch Ctr, University of Alberta, Edmonton, AB, Canada, ¹¹School of Nursing, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases…
Abstract Number: 357 • 2012 ACR/ARHP Annual Meeting
Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?
Dietmar MJ Krause¹, Bernadette Gabriel², Gertraud Herborn³ and Rolf Rau⁴, ¹Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, ²Private Practice, Gladbeck, Germany, ³Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany, ⁴Evangelisches Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA). MTX shows effects on disease activity, radiologic progression and mortality. These…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].